

# Influenza Session

Emmanuel (Chip) Walter, MD, MPH

Chair, Influenza Work Group

Advisory Committee on Immunization Practices

February 21, 2018



# Influenza Work Group

## **ACIP Members**

Emmanuel (Chip) Walter (Chair)  
Robert Atmar  
Ed Belongia  
Hank Bernstein  
Peter Szilagyi

## ***Ex Officio* Members**

Karin Bok (HHS)  
David Cho (FDA)  
Lucia Lee (FDA)  
Cynthia Nollezzi (FDA)  
Roshan Ramanathan (FDA)  
Chris Roberts (NIH)

## **Consultants**

Jeff Duchin  
Wendy Keitel  
Ruth Karron  
Jamie Loehr

## **Liaison Representatives**

Kevin Ault (ACOG)  
Sarah Coles (AAFP)  
Sarah Despres (Consumer representative)  
Jan Englund (PIDS)  
Sandra Fryhofer (ACP; AMA)  
Ian Gemmill (NACI)  
Marie-Michèle Léger (AAPA)  
Susan Lett (CSTE)  
Flor Munoz (AAP)  
Kathy Neuzil (IDSA)  
William Schaffner (NFID)  
Rob Schechter (AIM)  
Ken Schmader (AGS)  
Patsy Stinchfield (NAPNAP)  
Rob Stirling (NACI)  
Tamara Sheffield (AHIP)  
Matthew Zahn (NACCHO)

# Recap of Influenza Session, October 2017

- Updates on influenza surveillance, vaccine coverage, and live attenuated influenza vaccine
- Discussion of Vaccine Safety Datalink study of spontaneous abortion following inactivated influenza vaccine

# Workgroup Activities Since October 2017 Meeting

- Discussion of LAIV
  - Combined US Individual patient-level data analysis of LAIV effectiveness
  - Systematic review of LAIV effectiveness
  - Update from MedImmune on U.S. Pediatric shedding/immunogenicity study

# Agenda Overview

- **Efficacy of Fluarix Quadrivalent in Children 6 through 35 Months of Age**
  - Dr. Leonard Friedland (GlaxoSmithKline)
- **Surveillance Update**
  - Ms. Lynnette Brammer (CDC/NCIRD/Influenza Division)
- **Vaccine Effectiveness Update**
  - Dr. Brendan Flannery (CDC/NCIRD/Influenza Division)
- **Results of a randomized trial of a new H1N1 LAIV strain in US Children**
  - Dr. Raburn Mallory (MedImmune/AstraZeneca)
- **Review of LAIV effectiveness for 2- through 17-year-olds**
  - Dr. Lisa Grohskopf (CDC/NCIRD/Influenza Division)
- **Considerations and Proposed Recommendations**
  - Dr. Lisa Grohskopf (CDC/NCIRD/Influenza Division)